{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:27:50Z","timestamp":1792074470122,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12010-022-04190-2","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T06:02:31Z","timestamp":1666245751000},"page":"1014-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Identification of Selective PPAR-\u03b3 Modulators by Combining Pharmacophore Modeling, Molecular Docking, and Adipogenesis Assay"],"prefix":"10.1007","volume":"195","author":[{"given":"Yunwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagashree","family":"KS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowramma","family":"Byran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2666-0878","authenticated-orcid":false,"given":"Praveen Thaggikuppe","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"4190_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1475-2840-2-4","volume":"2","author":"A Tenenbaum","year":"2003","unstructured":"Tenenbaum, A., Fisman, E. Z., & Motro, M. (2003). Metabolic syndrome and type 2 diabetes mellitus: Focus on peroxisome proliferator activated receptors (PPAR). Cardiovascular Diabetology, 2, 4.","journal-title":"Cardiovascular Diabetology"},{"key":"4190_CR2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.69054","volume":"12","author":"S Wang","year":"2022","unstructured":"Wang, S., Lin, Y., Gao, L., Yang, Z., Lin, J., Ren, S., Li, F., Chen, J., Wang, Z., Dong, Z., Sun, P., & Wu, B. (2022). PPAR-gamma integrates obesity and adipocyte clock through epigenetic regulation of Bmal1. Theranostics, 12, 1589\u20131606.","journal-title":"Theranostics"},{"key":"4190_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1124\/mol.111.076679","volume":"82","author":"Y Tan","year":"2012","unstructured":"Tan, Y., Muise, E. S., Dai, H., Raubertas, R., Wong, K. K., Thompson, G. M., Wood, H. B., Meinke, P. T., Lum, P. Y., & Thompson, J. R. (2012). Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) modulators display attenuated and selective gene regulatory activity in comparison with PPAR\u03b3 full agonists. Molecular Pharmacology, 82, 68\u201379.","journal-title":"Molecular Pharmacology"},{"key":"4190_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","volume":"79","author":"P Tontonoz","year":"1994","unstructured":"Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994). Stimulation of adipogenesis in fibroblasts by PPAR\u03b32, a lipid-activated transcription factor. Cell, 79, 1147\u20131156.","journal-title":"Cell"},{"key":"4190_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1210\/er.2003-0036","volume":"25","author":"C Knouff","year":"2004","unstructured":"Knouff, C., & Auwerx, J. (2004). Peroxisome proliferator-activated receptor-\u03b3 calls for activation in moderation: Lessons from genetics and pharmacology. Endocrine Reviews, 25, 899\u2013918.","journal-title":"Endocrine Reviews"},{"key":"4190_CR6","doi-asserted-by":"crossref","unstructured":"Helal, M., Ali, M. A., Nadrin, A. H., Awad, Y. I., Younis, N. K., Alasyed, B. M., Jamal, M., Eid, D. H., Soliman, H. A., Eissa, S. A. and Ragab, M. (2022). Association between IRS-1, PPAR-gamma and LEP genes polymorphisms and growth traits in rabbits. Anim Biotechnol, 1\u20139.","DOI":"10.1080\/10495398.2022.2092743"},{"key":"4190_CR7","doi-asserted-by":"crossref","unstructured":"Lange, N. F., Graf, V., Caussy, C. & Dufour, J. F. (2022). PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients. International Journal Molecular Science, 23.","DOI":"10.3390\/ijms23084305"},{"key":"4190_CR8","doi-asserted-by":"crossref","unstructured":"Teixeira, C., Sousa, A. P., Santos, I., Rocha, A. C., Alencastre, I., Pereira, A. C., Martins-Mendes, D., Barata, P., Baylina, P. & Fernandes, R. (2022). Enhanced 3T3-L1 differentiation into adipocytes by pioglitazone pharmacological activation of peroxisome proliferator activated receptor-gamma (PPAR-gamma). Biology (Basel), 11.","DOI":"10.3390\/biology11060806"},{"key":"4190_CR9","doi-asserted-by":"publisher","first-page":"174562","DOI":"10.1016\/j.ejphar.2021.174562","volume":"912","author":"AH Faghfouri","year":"2021","unstructured":"Faghfouri, A. H., Khajebishak, Y., Payahoo, L., Faghfuri, E., & Alivand, M. (2021). PPAR-gamma agonists: Potential modulators of autophagy in obesity. European Journal of Pharmacology, 912, 174562.","journal-title":"European Journal of Pharmacology"},{"key":"4190_CR10","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1038\/s41467-022-29633-6","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu, C., Xiong, Q., Li, Q., Lin, W., Jiang, S., Zhang, D., Wang, Y., Duan, X., Gong, P., & Kang, N. (2022). CHD7 regulates bone-fat balance by suppressing PPAR-gamma signaling. Nature Communications, 13, 1989.","journal-title":"Nature Communications"},{"key":"4190_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"RE Soccio","year":"2014","unstructured":"Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014). Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell metabolism, 20, 573\u2013591.","journal-title":"Cell metabolism"},{"key":"4190_CR12","doi-asserted-by":"crossref","unstructured":"Yokoi, T. (2010), in Adverse drug reactions: Handbook of Experimental Pharmacology, 419\u2013435.","DOI":"10.1007\/978-3-642-00663-0_14"},{"key":"4190_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/816856","volume":"2015","author":"AJ Kroker","year":"2015","unstructured":"Kroker, A. J., & Bruning, J. B. (2015). Review of the structural and dynamic mechanisms of PPAR\u03b3partial agonism. PPAR Research, 2015, 1\u201315.","journal-title":"PPAR Research"},{"key":"4190_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfm021","volume":"97","author":"H Jaeschke","year":"2007","unstructured":"Jaeschke, H. (2007). Troglitazone hepatotoxicity: Are we getting closer to understanding idiosyncratic liver injury? Toxicological Sciences, 97, 1\u20133.","journal-title":"Toxicological Sciences"},{"key":"4190_CR15","doi-asserted-by":"crossref","unstructured":"Cheng, D., Gao, H. & Li, W. (2018). Wp\u0142yw d\u0142ugotrwa\u0142ego stosowania rozyglitazonu na zdarzenia sercowo-naczyniowe \u2014 przegl\u0105d systematyczny i metaanaliza. Endokrynologia Polska, 69.","DOI":"10.5603\/EP.a2018.0036"},{"key":"4190_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/dme.12627","volume":"32","author":"REJ Ryder","year":"2015","unstructured":"Ryder, R. E. J. (2015). Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabetic Medicine, 32, 305\u2013313.","journal-title":"Diabetic Medicine"},{"key":"4190_CR17","doi-asserted-by":"crossref","unstructured":"Korhonen, P., Heintjes, E. M., Williams, R., Hoti, F., Christopher, S., Majak, M., Kool-Houweling, L., Strongman, H., Linder, M., Dolin, P. and Bahmanyar, S. (2016) Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Bmj.","DOI":"10.1136\/bmj.i3903"},{"key":"4190_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/dme.12144","volume":"30","author":"M Ferwana","year":"2013","unstructured":"Ferwana, M., Firwana, B., Hasan, R., Al-Mallah, M. H., Kim, S., Montori, V. M., & Murad, M. H. (2013). Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies. Diabetic Medicine, 30, 1026\u20131032.","journal-title":"Diabetic Medicine"},{"key":"4190_CR19","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2337\/db06-0618","volume":"55","author":"T Allen","year":"2006","unstructured":"Allen, T., Zhang, F., Moodie, S. A., Clemens, L. E., Smith, A., Gregoire, F., Bell, A., Muscat, G. E., & Gustafson, T. A. (2006). Halofenate is a selective peroxisome proliferator\u2013activated receptor \u03b3 modulator with antidiabetic activity. Diabetes, 55, 2523\u20132533.","journal-title":"Diabetes"},{"key":"4190_CR20","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1681\/ASN.2009060673","volume":"20","author":"C Nofziger","year":"2009","unstructured":"Nofziger, C., & Blazer-Yost, B. L. (2009). PPAR\u03b3 agonists, modulation of ion transporters, and fluid retention. Journal of the American Society of Nephrology, 20, 2481\u20132483.","journal-title":"Journal of the American Society of Nephrology"},{"key":"4190_CR21","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.2337\/diacare.27.8.2096","volume":"27","author":"TA Elasy","year":"2004","unstructured":"Elasy, T. A., & Griffin, M. (2004). Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association: Response to Nesto. Diabetes Care, 27, 2096\u20132096.","journal-title":"Diabetes Care"},{"key":"4190_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","volume":"23","author":"B Cariou","year":"2012","unstructured":"Cariou, B., Charbonnel, B., & Staels, B. (2012). Thiazolidinediones and PPAR\u03b3 agonists: Time for a reassessment. Trends in Endocrinology & Metabolism, 23, 205\u2013215.","journal-title":"Trends in Endocrinology & Metabolism"},{"key":"4190_CR23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbalip.2007.01.007","volume":"1771","author":"V Zoete","year":"2007","unstructured":"Zoete, V., Grosdidier, A., & Michielin, O. (2007). Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1771, 915\u2013925.","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids"},{"key":"4190_CR24","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1210\/me.2013-1427","volume":"28","author":"MB Wright","year":"2014","unstructured":"Wright, M. B., Bortolini, M., Tadayyon, M., & Bopst, M. (2014). Minireview: Challenges and opportunities in development of PPAR agonists. Molecular Endocrinology, 28, 1756\u20131768.","journal-title":"Molecular Endocrinology"},{"key":"4190_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1101\/gad.237628.114","volume":"28","author":"SE Step","year":"2014","unstructured":"Step, S. E., Lim, H.-W., Marinis, J. M., Prokesch, A., Steger, D. J., You, S.-H., Won, K.-J., & Lazar, M. A. (2014). Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPAR\u03b3-driven enhancers. Genes & Development, 28, 1018\u20131028.","journal-title":"Genes & Development"},{"key":"4190_CR26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1210\/er.2006-0033","volume":"27","author":"ME Trujillo","year":"2006","unstructured":"Trujillo, M. E., & Scherer, P. E. (2006). Adipose tissue-derived factors: Impact on health and disease. Endocrine Reviews, 27, 762\u2013778.","journal-title":"Endocrine Reviews"},{"key":"4190_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Bostr\u00f6m, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., & Bl\u00fcher, M. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5. Nature, 466, 451.","journal-title":"Nature"},{"key":"4190_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1210\/jc.2006-1268","volume":"92","author":"AM Sharma","year":"2006","unstructured":"Sharma, A. M., & Staels, B. (2006). Peroxisome proliferator-activated receptor \u03b3 and adipose tissue\u2014Understanding obesity-related changes in regulation of lipid and glucose metabolism. The Journal of Clinical Endocrinology & Metabolism, 92, 386\u2013395.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"4190_CR29","doi-asserted-by":"publisher","first-page":"7443","DOI":"10.1038\/ncomms8443","volume":"6","author":"DP Marciano","year":"2015","unstructured":"Marciano, D. P., Kuruvilla, D. S., Boregowda, S. V., Asteian, A., Hughes, T. S., Garcia-Ordonez, R., Corzo, C. A., Khan, T. M., Novick, S. J., & Park, H. (2015). Pharmacological repression of PPAR\u03b3 promotes osteogenesis. Nature Communications, 6, 7443.","journal-title":"Nature Communications"},{"key":"4190_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14740330802597821","volume":"8","author":"C Rizos","year":"2009","unstructured":"Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009). How safe is the use of thiazolidinediones in clinical practice? Expert Opinion on Drug Safety, 8, 15\u201332.","journal-title":"Expert Opinion on Drug Safety"},{"key":"4190_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/25931","volume":"395","author":"RT Nolte","year":"1998","unstructured":"Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998). Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-\u03b3. Nature, 395, 137.","journal-title":"Nature"},{"key":"4190_CR32","doi-asserted-by":"crossref","unstructured":"Thangavel, N., Al Bratty, M., Akhtar Javed, S., Ahsan, W. and Alhazmi, H. A. (2017). Targeting peroxisome proliferator-activated receptors using thiazolidinediones: Strategy for design of novel antidiabetic drugs. International journal of medicinal chemistry, 2017.","DOI":"10.1155\/2017\/1069718"},{"key":"4190_CR33","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.str.2007.07.014","volume":"15","author":"JB Bruning","year":"2007","unstructured":"Bruning, J. B., Chalmers, M. J., Prasad, S., Busby, S. A., Kamenecka, T. M., He, Y., Nettles, K. W., & Griffin, P. R. (2007). Partial agonists activate PPAR\u03b3 using a helix 12 independent mechanism. Structure, 15, 1258\u20131271.","journal-title":"Structure"},{"key":"4190_CR34","doi-asserted-by":"crossref","unstructured":"Capelli, D., Cerchia, C., Montanari, R., Loiodice, F., Tortorella, P., Laghezza, A., Cervoni, L., Pochetti, G. & Lavecchia, A. (2016). Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode. Scientific Reports, 6.","DOI":"10.1038\/srep34792"},{"key":"4190_CR35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1021\/bi048032c","volume":"44","author":"S-H Sheu","year":"2005","unstructured":"Sheu, S.-H., Kaya, T., Waxman, D. J., & Vajda, S. (2005). Exploring the binding site structure of the PPAR\u03b3 ligand-binding domain by computational solvent mapping\u2020. Biochemistry, 44, 1193\u20131209.","journal-title":"Biochemistry"},{"key":"4190_CR36","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.2174\/092986709788186165","volume":"16","author":"A Farce","year":"2009","unstructured":"Farce, A., Renault, N., & Chavatte, P. (2009). Structural insight into PPAR\u03b3 ligands binding. Current Medicinal Chemistry, 16, 1768\u20131789.","journal-title":"Current Medicinal Chemistry"},{"key":"4190_CR37","doi-asserted-by":"publisher","first-page":"7768","DOI":"10.1021\/jm800733h","volume":"51","author":"R Montanari","year":"2008","unstructured":"Montanari, R., Saccoccia, F., Scotti, E., Crestani, M., Godio, C., Gilardi, F., Loiodice, F., Fracchiolla, G., Laghezza, A., Tortorella, P., Lavecchia, A., Novellino, E., Mazza, F., Aschi, M., & Pochetti, G. (2008). Crystal structure of the peroxisome proliferator-activated receptor \u03b3 (ppar\u03b3) ligand binding domain complexed with a novel partial agonist: A new region of the hydrophobic pocket could be exploited for drug design. Journal of Medicinal Chemistry, 51, 7768\u20137776.","journal-title":"Journal of Medicinal Chemistry"},{"key":"4190_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/1570193X11310010005","volume":"10","author":"P Thaggikuppe Krishnamurthy","year":"2013","unstructured":"Thaggikuppe Krishnamurthy, P., JogheeNanjanChandrasekar, M., & JogheeNanjan, M. (2013). Newer approaches to the discovery of glitazones. Mini-Reviews in Organic Chemistry, 10, 66\u201372.","journal-title":"Mini-Reviews in Organic Chemistry"},{"key":"4190_CR39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0092-8674(00)00188-4","volume":"103","author":"Y Shang","year":"2000","unstructured":"Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. (2000). Cofactor dynamics and sufficiency in estrogen receptor\u2013regulated transcription. Cell, 103, 843\u2013852.","journal-title":"Cell"},{"key":"4190_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1210\/er.2003-0023","volume":"25","author":"CL Smith","year":"2004","unstructured":"Smith, C. L., & O\u2019malley, B. W. (2004). Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews, 25, 45\u201371.","journal-title":"Endocrine Reviews"},{"key":"4190_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/157340720903140119153500","volume":"9","author":"T Krishnamurthy Praveen","year":"2013","unstructured":"Krishnamurthy Praveen, T., JogheeNanjanChandrasekar, M., & JogheeNanjan, M. (2013). Novel glitazones with diverse peroxisome proliferator activated receptor modulatory potential. Current Bioactive Compounds, 9, 221\u2013234.","journal-title":"Current Bioactive Compounds"},{"key":"4190_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","volume":"89","author":"F Denizot","year":"1986","unstructured":"Denizot, F., & Lang, R. (1986). Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of Immunological Methods, 89, 271\u2013277.","journal-title":"Journal of Immunological Methods"},{"key":"4190_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ab.2012.03.005","volume":"425","author":"K Zebisch","year":"2012","unstructured":"Zebisch, K., Voigt, V., Wabitsch, M., & Brandsch, M. (2012). Protocol for effective differentiation of 3T3-L1 cells to adipocytes. Analytical Biochemistry, 425, 88\u201390.","journal-title":"Analytical Biochemistry"},{"key":"4190_CR44","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1210\/me.2002-0217","volume":"17","author":"JP Berger","year":"2003","unstructured":"Berger, J. P., Petro, A. E., Macnaul, K. L., Kelly, L. J., Zhang, B. B., Richards, K., Elbrecht, A., Johnson, B. A., Zhou, G., & Doebber, T. W. (2003). Distinct properties and advantages of a novel peroxisome proliferator-activated protein \u03b3 selective modulator. Molecular Endocrinology, 17, 662\u2013676.","journal-title":"Molecular Endocrinology"},{"key":"4190_CR45","doi-asserted-by":"publisher","first-page":"41487","DOI":"10.1038\/srep41487","volume":"7","author":"W Yi","year":"2017","unstructured":"Yi, W., Shi, J., Zhao, G., Zhou, X. E., Suino-Powell, K., Melcher, K., & Xu, H. E. (2017). Identification of a novel selective ppar\u03b3 ligand with a unique binding mode and improved therapeutic profile in vitro. Scientific Reports, 7, 41487.","journal-title":"Scientific Reports"},{"key":"4190_CR46","doi-asserted-by":"crossref","unstructured":"Chen, Y., Ma, H., Zhu, D., Zhao, G., Wang, L., Fu, X. & Chen, W. (2017). Discovery of novel insulin sensitizers: Promising approaches and targets. PPAR Research, 2017.","DOI":"10.1155\/2017\/8360919"},{"key":"4190_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1155\/2008\/786359","volume":"2008","author":"JA Pinaire","year":"2008","unstructured":"Pinaire, J. A., Miller, A. R., & Gregoire, F. M. (2008). Development of synthetic modulators of PPARs: Current challenges and future opportunities. PPAR Research, 2008, 7.","journal-title":"PPAR Research"},{"key":"4190_CR48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1097-2765(00)80210-5","volume":"4","author":"N Kubota","year":"1999","unstructured":"Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., & Sugiyama, T. (1999). PPAR\u03b3 mediates high-fat diet\u2013induced adipocyte hypertrophy and insulin resistance. Molecular cell, 4, 597\u2013609.","journal-title":"Molecular cell"},{"key":"4190_CR49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejphar.2012.03.033","volume":"684","author":"S Chaudhary","year":"2012","unstructured":"Chaudhary, S., Dube, A., Kothari, V., Sachan, N., & Upasani, C. D. (2012). NS-1: A novel partial peroxisome proliferator-activated receptor \u03b3 agonist to improve insulin sensitivity and metabolic profile. European Journal of Pharmacology, 684, 154\u2013160.","journal-title":"European Journal of Pharmacology"},{"key":"4190_CR50","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1073\/pnas.96.11.6102","volume":"96","author":"JL Oberfield","year":"1999","unstructured":"Oberfield, J. L., Collins, J. L., Holmes, C. P., Goreham, D. M., Cooper, J. P., Cobb, J. E., Lenhard, J. M., Hull-Ryde, E. A., Mohr, C. P., & Blanchard, S. G. (1999). A peroxisome proliferator-activated receptor \u03b3 ligand inhibits adipocyte differentiation. Proceedings of the National Academy of Sciences, 96, 6102\u20136106.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"4190_CR51","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1016\/j.bmcl.2011.06.088","volume":"21","author":"M Sime","year":"2011","unstructured":"Sime, M., Allan, A. C., Chapman, P., Fieldhouse, C., Giblin, G. M., Healy, M. P., Lambert, M. H., Leesnitzer, L. M., Lewis, A., & Merrihew, R. V. (2011). Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPAR\u03b3 partial agonist. Bioorganic & Medicinal Chemistry Letters, 21, 5568\u20135572.","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"4190_CR52","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/jm021027r","volume":"46","author":"S Ebdrup","year":"2003","unstructured":"Ebdrup, S., Pettersson, I., Rasmussen, H. B., Deussen, H.-J., Frost Jensen, A., Mortensen, S. B., Fleckner, J., Pridal, L., Nygaard, L., & Sauerberg, P. (2003). Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor \u03b1\/\u03b3 agonist ragaglitazar. Journal of Medicinal Chemistry, 46, 1306\u20131317.","journal-title":"Journal of Medicinal Chemistry"},{"key":"4190_CR53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.tibs.2004.04.006","volume":"29","author":"L Nagy","year":"2004","unstructured":"Nagy, L., & Schwabe, J. W. (2004). Mechanism of the nuclear receptor molecular switch. Trends in Biochemical Sciences, 29, 317\u2013324.","journal-title":"Trends in Biochemical Sciences"},{"key":"4190_CR54","doi-asserted-by":"publisher","first-page":"9530","DOI":"10.1038\/srep09530","volume":"5","author":"C Liu","year":"2015","unstructured":"Liu, C., Feng, T., Zhu, N., Liu, P., Han, X., Chen, M., Wang, X., Li, N., Li, Y., & Xu, Y. (2015). Identification of a novel selective agonist of PPAR\u03b3 with no promotion of adipogenesis and less inhibition of osteoblastogenesis. Scientific Reports, 5, 9530.","journal-title":"Scientific Reports"},{"key":"4190_CR55","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1210\/me.2005-0171","volume":"20","author":"E Burgermeister","year":"2006","unstructured":"Burgermeister, E., Schnoebelen, A., Flament, A., Benz, Jr., Stihle, M., Gsell, B., Rufer, A., Ruf, A., Kuhn, B., & M\u00e4rki, H. P. (2006). A novel partial agonist of peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3) recruits PPAR\u03b3-coactivator-1\u03b1, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Molecular Endocrinology, 20, 809\u2013830.","journal-title":"Molecular Endocrinology"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-022-04190-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-022-04190-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-022-04190-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T05:38:14Z","timestamp":1701236294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-022-04190-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4190"],"URL":"https:\/\/doi.org\/10.1007\/s12010-022-04190-2","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"28 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}